We describe a novel point mutation in the fourth exon of human factor IX (encoding the first EGF-like domain) in which cytosine is substituted for adenosine at position 10,401, resulting in the substitution of proline for glutamine at position 60 in the polypeptide chain. Sequence analysis of all eight exons, all exon-intron junctions, 160 base pairs (bp) of DNA 5' to the proposed translation start site, and 60 bp 3' to the translation termination site shows no other difference from the normal factor IX gene, with the exception of a previously described benign polymorphism at position 148 in the protein (Ala -Thr). The affected subject has severe hemophilia 6 with no detectable factor IX activity despite normal factor IX antigen levels. We purified the abnormal factor IX by immunoaf-EMOPHILIA B results from the lack of factor IX H activity and accounts for 10% to 15% of congenital coagulant factor deficiencies. The human factor IX gene consists of eight exons and seven introns, and is located near the end of the long arm of the X chromosome (Xq26-27)'; the gene has been sequenced by Yoshitake et a12 and spans 34,000 base pairs (bp). A number of genetic defects have been shown to cause hemophilia B; these include deletions or complete7-") and a variety of point mutations affecting the catalytic,' '-I4 a~tivation,'~.'~ EGF-like,'8-20 Gla,2'
H activity and accounts for 10% to 15% of congenital coagulant factor deficiencies. The human factor IX gene consists of eight exons and seven introns, and is located near the end of the long arm of the X chromosome (Xq26-27)'; the gene has been sequenced by Yoshitake et a12 and spans 34,000 base pairs (bp). A number of genetic defects have been shown to cause hemophilia B; these include deletions or complete7-") and a variety of point mutations affecting the catalytic,' '-I4 a~tivation,'~.'~ EGF-like,'8-20 Gla, 2' propeptide:2-25 and 5' flanking region^^^.^^ of the protein, as well as a number of mutations causing premature termination c o d o n~,~~.~~ or mutations at exon-intron junction^.^'*^^ These mutations may result in the production of protein (crossreacting material, CRM) in varying amounts (CRM", CRMnCg, or CRMred), with varying degrees of enzymatic activity. Mutations with no activity (less than 1% of normal) are associated with severe hemophilia B, whereas those with partial activity are associated with moderate or mild disease.
We investigated the defect causing hemophilia B in a patient with severe disease despite normal factor IX protein levels. We report the molecular basis for this defect, which is designated factor IX,,, London.
MATERIALS AND METHODS
The subject of our study was diagnosed shortly after birth as having severe hemophilia B (factor IX activity less than 1%). He is followed at the Comprehensive Hemophilia Center at the University of North Carolina at Chapel Hill. He has no history of an inhibitor even though he has been treated with factor IX replacement on multiple occasions. The subject gave his informed consent for phlebotomy, and the studies were approved by the Committee for the Protection of Human Subjects at the University of North Carolina at Chapel Hill; the subject's mother gave similar informed consent.
DNA was prepared from 5 to 10 mL of whole blood (collected in EDTA) by the method of Blin and Stafford." Typical yields of DNA from 10 mL of blood were 150 pg. DNA was stored in Tris-EDTA at -2OOC before use.
Polymerase chain reaction (PCR). PCR was performed by the method of Saiki et al" using an automated thermal cycler (PerkinHumansubjects.
DNA preparation.
finity chromatography and demonstrated that its activation by factor Xla is markedly delayed compared with normal factor IX. Once activated, the abnormal factor IX binds antithrombin 111 in a 1:l molar ratio, and the activated protein demonstrates catalytic activity, suggesting an intact active site. The mutation creates a new 6stM restriction endonuclease cleavage site. Restriction with BstM shows the mutation in maternal DNA and offers the possibility of direct carrier status analysis and prenatal diagnosis in kindreds with this mutation. We designate this new mutation factor I X , , London. This is the only reported mutation in the first EGF-like domain that causes severe hemophilia B. 0 1990 by The American Society of Hematology.
Elmer Cetus, Norwalk, CT). The amount of DNA per reaction was 2 pg, dNTP concentration was 0.2 mmol/L, oligonucleotide primer concentrations were 1 pmol/L, the buffer was 10 mmol/L Tris (pH 8.3), 50 mmol/L KCI, 2.5 mmol/L MgCI,, 0.01% gelatin, and the total volume of each reaction was 100 pL. After adding 0.5 pL (2.5 U) Tag polymerase (Amplitaq, Perkin-Elmer Cetus), the reactions were overlaid with mineral oil (Sigma, St Louis, MO) and heated at 94OC for 10 minutes, with subsequent automated cycling of 30 rounds of 2 minutes at 55OC (primer annealing), 3 minutes at 72OC (extension), and 2 minutes at 94OC (melting). Oligomer primers used to amplify factor IX exons are listed in Table 1 .
Preparative and analytical agarose gel electrophoresis of DNA was performed in 1% agarose (Ultrapure, BRL, Gaithersburg, MD) in Tris-borate-EDTA buffer at 40 to 100 V. Preparative DNA electrophoresis was followed by excision of DNA bands under long-wave UV guidance, and maceration of these gel fragments in Tris-EDTA buffer/phenol/chloroform (100 pL each). The macerated gel fragments were frozen and thawed, then centrifuged in an Eppendorf microcentrifuge, and the supernatant extracted sequentially with phenol, phenol-chloroform, and chloroform before precipitation with absolute ethanol-sodium acetate and washing with 95% ethanol. The DNA obtained was dissolved in Tris-EDTA and frozen before further use.
EcoRI enzyme was obtained Agarose electrophoresis.
Restriction of DNA fragments. from New England Biolabs (Beverly, MA). Typically, 1 to 5 pg of DNA was digested with EcoRI enzyme in the buffer recommended by the manufacturer. The digested DNA was extracted with phenol, phenol-chloroform, and chloroform in succession, then precipitated with absolute ethanol-sodium acetate and washed with 95% ethanol. EcoRI digest fragments (approximately 4 pmol/mL) were incubated with EcoRIdigested mp18 or mp19 strains of M13 phage (0.8 pmol/mL), in the presence of 5 U T4 DNA ligase (New England Biolabs) at 14OC overnight in DNA ligation buffer described by Maniatis et al.'* Transfection of JMl03 cells with M13phage. Calcium chloridetreated JM103 Escherichia coli cells were used for transfection with M13 phage containing the DNA inserts as described above. Transfected clones were selected by plating on L-agar with noncompetent JM103 cells, 80 p L of 2% X-GAL (Sigma); and 20 pL of 2.5% isopropyl-thiogalactoside (Sigma), clear plaques were used to grow single-stranded M13 phage for dideoxy sequencing as described by Sanger et al.33 Analysis of sequence data was performed with the Beckman Microgenie computer program (Beckman, Palo Alto, CA).34
~
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BstYI was obtained from New England Biolabs and used to digest the PCR fragment containing the factor IXNCw London mutation. The enzyme was incubated with the DNA fragment in the recommended buffer at 6OoC for 2 to 4 hours. Analytical agarose electrophoresis of BstYI digest fragments was performed with 5% NuSieve agarose (Rockland, ME) in Tris-borate-EDTA buffer at 75 V.
One hundred milliliters of sodium citrate-anticoagulated plasma was obtained from our subject as the starting material for protein purification. The plasma was mixed with 100 mL DEAE-Sepharose CL6B (Pharmacia LKB, Piscataway, NJ) equilibrated with 50 mmol/L sodium citrate (pH 6.5), 10 mmol/L benzamidine, and 2 U/mL of heparin. The slurry was stirred for 1 hour at 4OC and then washed extensively with 50 mmol/L 2-[N-morpholino]ethanesulfonic acid (pH 6.5). 1 mmol/L benzamidine, and 50 mmol/L sodium chloride, poured into a Ligation of DNA into MI3 phage vectors.
BstYI digestion.
Purification of factor IXNm chromatography column, and eluted with the same buffer except that the sodium chloride concentration was raised to 600 mmol/L. The fractions containing factor IX antigen as determined by radioimmunoassay with monoclonal antibody (MoAb) A-5 and 1251-radiolabe.led MoAb A-1 in a microtiter assay'5 were pooled and diluted with water to a sodium chloride concentration of 150 mmol/L sodium chloride before loading on a column containing 2 mL of MoAb A-7 coupled to an Affiprep 10 matrix (BioRad, Richmond, CA). The column was washed with 20 mmol/L Tris (pH 7.4), 500 mmol/L sodium chloride, 20 mmol/L magnesium chloride, and then eluted with 20 mmol/L Tris (pH 7.4), 150 mmol/L sodium chloride, 20 mmol/L EDTA, and 1 mmol/L benzamidine. The factor IX-containing fractions were then pooled and concentrated with an Amicon ultrafiltration-concentration system in a buffer identical to the elution buffer without EDTA. The final volume of the concentrated factor IX,, was 1.4 mL, and the final yield of the protein was 140 pg (28% overall yield).
Factor XIa was prepared as described el~ewhere.'~ Approximately 40 pg of purified factor IX,,, Landon was diluted in 500 pL of 50 mmol/L Tris (pH 7.9, 150 mmol/L sodium chloride, 5 mmol/L calcium chloride, 0.01% PEG, and incubated with factor XIa (factor X1a:factor IX = 1:20)
at 37OC for 120 minutes. Aliquots were removed and subjected to SDS-PAGE" under reducing conditions (5% 8-mercaptoethanol), and visualized by a silver stain.'* Identical studies of normal factor IX were also performed at the same time.
Titration of factor IXa catalytic sites with antithrombin III. Factor IXa,, (100 nmol/L by radioimmunoassay) was mixed with various concentrations of antithrombin 111 (generous gift of Dr Frank Church, University of North Carolina) and heparin (5 pg/mL) and incubated in microtiter plates at room temperature for 30 minutes. Fifty microliters of each reaction mixture were then transferred to a separate well containing 24 pL of 100 mmol/L triethylamine (pH 8.0), 100 mmol/L sodium chloride, 0.1% polyethylene glycol, 0.2% bovine serum albumin, 6 pL of 1 pmol/L polylysine (Sigma), and 20 pL of 3 pmol/L factor X prepared as 
RESULTS
Using the strategy of PCR amplification of DNA fragments containing exons for the factor IX gene, restriction and subcloning into M I3 vectors. and dideoxy chain termination sequence analysis, we determined the sequence of 2295 bp of DNA from our subject. These included all eight exons for factor IX. all exon-intron junctions. 695 bp of intron sequence. and 160 bp 5' to the putative translation initiation site (Met ) and 60 bp 3' to the stop codon after Thr,,<. The amino acid sequence predicted by the nucleotide scquence differed from that published by Yoshitakc et al? at only two sita. We detected the benign polymorphism at position 148 (Ala -Thr) in the activation peptide as described by
McGraw et at"' and the novel point mutation in which an A to C transversion causes proline to substitute for glutamine at SO is in the first (type R) EGF-like domain of the factor IX molecule. The mutation was obtained by sequence analysis in both the sense and antisense strands of DNA and in two separate amplifications of DNA. ruling out errors of Tuqpolymerase DNA synthesis during K R . or errors of T7 DNA polymerase during dideoxy chain termination sequenceanalysis. The mutation isdemonstrated in thesequencing gel shown in Fig 1. The nucleotide change is predicted to c r a t e a new RsrYl restriction site within the PCR fragment bearing the mutation (Fig 2) . Therefore. the fragment was amplified from DNA from the subject, his mother. and a normal female control. The amplified fragments were then digested with RsrYI as shown in Fig 2. Both the subject and his mother show cleavage and generation of the predicted fragments with BsrYl whereas there is no cleavage in the normal control. Results of radioimmunoassay of the subject's plasma showed 106% of normal factor IX antigen levels. undergoes markedly delayed activation by factor Xla as compared with normal factor IX. There is persistence of factor IXn. an inactive intermediate form that consists of the heavy chain of factor IX attached to the activation peptide. However. with prolonged incubation there is eventual complete activation of factor IX,, ,-by factor Xla. When activation of factor IX-I . l h is performed at room temperature there is incomplete activation despite prolonged incubation (data not shown).
Titrations of activated factor IX and factor IX,, , -with antithrombin I l l (Fig 4) show that activated factor IXbinds as much antithrombin 111 per molecule of factor IXa as normal factor IXa. This suggats that on IX activity per microgram of protein for normal factor IXa. nmol/L) that the polylysine-catalyzcd rates of factor X activation by activated factor IX and by activated factor IX* 8-are comparable (Fig 4) .
PCR-smptifiod
When tested for the ability to correct the prolonged activated partial thromboplastin time of factor IX deficient
DISCUSSION
The mutation in this subject is previously unreported and. based on family history. appears to represent a de novo mutation. as is predicted to occur in perhaps one third of hemophilia patient^.^' The mutation creates a new BstYI restriction endonuclease cleavage site, and we confirmed that there is cleavage at this site in both the patient and his mother, suggesting that the original mutation may have occurred in her parents or other forebears (who are not available for analysis). The BstYI cleavage site resulting from the mutation makes it possible to offer direct, deterministic carrier detection, rather than probabilistic estimates of carrier status to females in kindreds with this mutation.
Because the glutamine at position 50 in factor IX is strictly conserved in a number of related coagulant proteins, including human factor IX,' bovine factor IX?' canine factor IX?3 human factor VII,@ and human factor X,4' as well as human protein C,& it may be inferred that the residue is of critical importance (Fig 5) . Glutamine does not appear at this position in human or mouse epidermal growth factors, suggesting that its structural importance is related directly to coagulant function, rather than binding of endothelial surfaces, for example.
Our results show that factor Ix,, London has no activity unless activated, and that activation by factor XIa is exceedingly slow as compared with normal factor IX. Even after activation the activity of factor IX,, Loadon is considerably less than normal.
The mechanism by which this mutation prevents factor IX activation is not clear. The mutation does not result in a change in charge and therefore should not directly alter electrostatic interactions within the factor IX molecule. Although proline is well-known to disrupt alpha helical secondary structure, the region around position 50 is unlikely to be part of an alpha helix, based on Chou and Fasman's empiric and the NMR studies on human4' and mouse49 epidermal growth factors. The effect of proline substitution at position 50 may be to change tertiary structure and, perhaps by steric hindrance, prevent binding of factor XIa by factor IX,, London.
Mutations in certain abnormal factor IX proteins have been demonstrated to cause abnormally slow or incomplete activation of factor IX by factor XIa. These include defects such as that in factor IXChape, Hill,1S in which cleavage at the Arg,,,-Ala,,, bond is abnormal due to substitution of histidine for arginine at position 145, and in factor IXHilo,17 in which cleavage of the Arg,,,-Val,,, bond is prevented by substitution of glutamine for arginine at position 180. The severe dysfunction of factor IX,,, London is consistent with that of the patient reported with the factor IXHilo defect', rather than the mild dysfunction of factor IXChapcl which, along with the persistence of the factor IXa species, suggests defective cleavage at the Arg,,,-Va1,,, bond in factor IX,,, London as the cause for the severe dysfunction of the protein.
We tested the ability of activated factor Ix,,, London to correct the aPTT of factor IX deficient plasma and found that the activated factor IX,, London has approximately 17% of the normal ability of factor IXa to correct the aPTT in terms of units of factor IX activity per microgram of activated factor IX (1.9 v 11.3 U activity per microgram protein). Thus, once activated, factor IX,,, London has activity levels comparable with those of other abnormal factor IX molecules with mutations in the first EGF-like domain. It seems that delayed activation of factor IX,,, London is the chief reason for its lack of factor IX activity, though the interactions of the abnormal factor 1X molecule with calcium, lipids, factor VIII, factor X, and endothelial surfaces remain to be studied.
The factor IX defects previously reported in the first EGF-like domain are all associated with mild hemophilia B.
These included factor IXAlabama (Asp,, -Gly, 10% of normal activity)," factor IXLondon , (Pro,, -Ala, 10% of normal activity),20 factor IXDurham (Gly,, -Ser, 14% of normal activity)," and factor IXbhn (&OH Asp,, -Gly, 8% of normal activity).*' These are shown in Fig 6 .
In addition to its delayed activation, the lack of factor IX activity in our subject might occur by one of several other mechanisms. It has been proposed that in factor IX and other coagulant proteins there is a calcium binding site distinct from the Gla domain, with a much higher affinity for calcium. 50 This site in factor IX may include @-OH aspartic acid and other negatively charged amino acids in the first EGF-like domain. Evidence for such sites in factor IX," protein C,5' bovine factor X,52,53 and bovine protein SN has been presented. One model proposes that the charged residues Asp,,, Asp,,, and /3-hydroxy-aspartic acid, form a charged surface as part of a &pleated sheet in the first EGF-like domain," and that these may participate in highaffinity calcium binding separate from that of the Gla domain. It is possible that calcium binding is also abnormal in factor IX,,, London, perhaps as a consequence of disruption of the high affinity binding site in this region.
It has also been proposed that the EGF-like domains in factor IX participate in factor VI11 binding. In one wellstudied variant, factor IXAlabama (Asp,, -Gly), there is a diminished effect of factor VI11 on factor IX-mediated activation of factor X.', If this region of the protein is disrupted by substitution of proline for glutamine at position 50, it is possible that factor VI11 binding is also disturbed in the factor IX,,, variant. Further functional studies of this mutant protein should help define the role of the EGF domain in general, and residue 50 in particular, in the XIa mediated activation of IX and in the IXa mediated activation of x.
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